GCC and German rheumatologists plan to establish a Spondyloarthritis Center of Excellence in partnership with Abbvie Biopharmaceuticals, a global, research-based biopharmaceutical company.
Rheumatologists from around the GCC recen
More than 350 international and regional rheumatology experts will discuss experiences and cutting-edge knowledge in the field of rheumatology and clinical immunology at an upcoming meeting in Abu Dhabi.
The third Abu Dhabi Advanc
UAE's National Health Insurance Company, Daman has added three new programmes to its health support services.
The programmes include support for colorectal and cervical cancers and rheumatoid arthritis, said a statement.
A programme to tackle the need for early diagnosis and management of rheumatoid arthritis has been set up in Bahrain by online medical resource organisation ENHANCE.
The ENHANCE Centre of Excellence at the King Hamad University Ho
Roche said on Wednesday that a trial had shown its rheumatoid arthritis drug RoActemra was more effective in reducing swelling and tenderness in joints than Abbott Laboratories' top-selling Humira when given as a single treatment.
Having both ovaries removed before age 45 is strongly associated with low-bone mineral density and arthritis in later years, according to a new study by Johns Hopkins oncologists and epidemiologists.
The analysis covered several thousand w
Roche's rheumatoid arthritis drug RoActemra helps treat patients with the painful and debilitating disease regardless of whether it is given on its own or in combination with another drug, a late-stage study showed.
The news could boost Ro
Novartis AG's gout treatment hopeful gives patients better pain relief and significantly cuts the risk of new attacks, two late stage studies showed, giving the drugmaker's pipeline another boost.
Ilaris, or ACZ885, is seen as a key drug f
Pfizer said that its experimental rheumatoid arthritis drug met the main goals of a late-stage clinical trial, a welcome boost for the world's largest drugmaker as it seeks new products to offset those that are losing patent protection.
Hoffmann–La Roche, leader in research-focused healthcare, has presented the latest results about systemic juvenile idiopathic arthritis (sJIA) at a rheumatism congress in Beirut.
The 2010 European League Against Rheumatism (Eular) congress